Malaria is a significant public health problem in developing countries, including Pakistan, with an annual mortality rate of 50,000 2.6 million cases in 2018. Pakistan continues to be among the top four countries with the highest number of anticipated malaria cases in the region. This descriptive cross-sectional study determined the unit cost of antimalarial prescriptions, compared average treatment costs, and assessed any differences in cost across prescriber types and medication categories. Using purposive sampling, 300 prescriptions of uncomplicated malaria were collected from physicians and consultants practicing at two public tertiary care hospitals in Lahore. The cost of drugs was calculated on the basis of the standard retail price set by the pharmaceutical company. The data were analyzed via SPSS version 25, frequencies were calculated, and two-way ANOVA was performed. The results highlighted that the unit cost of antimalarials prescribed by physicians ranged from Pakistani rupees (PKR) 21-30, whereas the majority of combination therapies for physicians cost up to PKR 50. In comparison, antimalarials prescribed by consultants had unit costs between PKR 31 and 40, with combination therapies falling into either a low-cost band (PKR 1–50) or a higher-cost band (PKR 201–300). Two-way ANOVA revealed a statistically significant interaction between prescriber type and medication category in relation to treatment cost (p = 0.002). The study concluded that physicians prescribe lower-cost unit doses and combinations of antimalarial medications than consultants do, and there are significant differences in treatment costs on the basis of prescriber type and the category of medication prescribed. Future research should explore qualitative determinants of prescriber behavior to guide national malaria control and health policy.